Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts

Since my previous coverage on Sagimet Biosciences Inc (NASDAQ: SGMT ), the stock has traded a bit sideways, down just 2% over the past month. However, last month we got some very nice updates from management onI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the r ...